Can IgA nephropathy occur in the absence of hypertension?

Can IgA Nephropathy Occur Without Hypertension?

Yes, IgA nephropathy absolutely occurs without hypertension—in fact, the majority of patients present without hypertension at diagnosis. Only 12% of patients have hypertension at initial presentation, though this increases to approximately 33% during follow-up 1.

Clinical Presentation and Natural History

IgA nephropathy commonly presents in normotensive patients, typically with:

• Microscopic or macroscopic hematuria
• Variable degrees of proteinuria
• Normal or near-normal blood pressure at diagnosis

The absence of hypertension at presentation does not exclude IgA nephropathy and should not delay diagnostic evaluation or kidney biopsy when clinically indicated.

Development of Hypertension Over Time

While many patients are normotensive initially, hypertension frequently develops during disease progression:

• Survival statistics show that only 45% of patients remain normotensive 10 years after renal biopsy 2
• The development of hypertension during follow-up is a marker of poor prognosis 2
• When hypertension becomes established, renal survival drops to approximately 70% at 3 years after hypertension diagnosis 2

Prognostic Implications

The presence or absence of hypertension has important prognostic significance:

Normotensive patients 1:

• Lower incidence of glomerulosclerosis
• Better tubular preservation
• Cumulative renal survival of 91% at 8 years
• Chronic renal failure occurs in only 14%

Hypertensive patients 1:

• Higher incidence of glomerulosclerosis and vascular changes
• Cumulative renal survival of 78% at 8 years (p<0.05)
• Chronic renal failure occurs in 42%
• Uncontrolled hypertension causes rapid deterioration to end-stage renal failure within 3 years versus 8 years when controlled

Management Considerations for Normotensive Patients

Even in normotensive IgA nephropathy patients, the KDIGO 2025 guidelines recommend specific approaches 3:

• All patients with IgAN should be treated with optimized maximally tolerated RAS blockade (ACEi or ARB) unless contraindications exist (low blood pressure, bilateral renal artery stenosis, hyperkalemia) 3
• For patients at risk of progressive kidney function loss, consider adding SGLT2 inhibitors or sparsentan 3
• The 2021 KDIGO guidelines note it may be reasonable to delay ACEi/ARB initiation in normotensive patients with podocytopathy expected to respond rapidly to immunosuppression 4

Common Pitfalls to Avoid

1. Do not assume hypertension must be present for IgA nephropathy diagnosis—most patients are normotensive at presentation
2. Do not delay biopsy in normotensive patients with persistent hematuria and proteinuria
3. Monitor blood pressure closely during follow-up—the development of hypertension signals disease progression and warrants treatment intensification
4. Recognize that normotensive patients may still have abnormal circadian blood pressure patterns—ambulatory monitoring shows absent nocturnal dipping even before overt hypertension develops 5